LONDON: Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, announced that Shaun Chilton has been appointed Non-Executive Chairman replacing Eliot Forster, who is also stepping down from the Board. The changes…
LONDON, UK: Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announced today that it has acquired Coris Bioconcept SRL (“Coris”) for an upfront cash consideration of £7.4 million (on a debt-free/cash-free…
LONDON, UK: Avacta Group plc announced that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples and, in this small study, outperformed two lateral flow antigen tests…
LONDON: Avacta Group has entered into a global distribution agreement with ABCAM plcto sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer reagents. Avacta has developed Affimer reagents which can be used in a high performance ELISA laboratory test to…
LONDON: Avacta Group has entered into a commercial partnership with Mologic Ltd to accelerate to market Avacta’s AffiDX SARS-CoV-2 lateral flow rapid antigen test. Avacta will also support antigen testing in low and middle income countries by providing access to…
LONDON: Avacta Group plc has entered into a collaboration agreement with Bruker Corporation to evaluate the Affimer-based, bead assisted mass spectrometry (BAMSTM) SARS-CoV-2 assay, that the Group has developed with Adeptrix Inc.. Bruker is one of the world’s leading analytical…
LONDON: Avacta Group plc has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical Co. Ltd., a leading Korean pharmaceutical company, and to enter into a collaboration and license agreement for the joint venture to develop the…
LONDON: Avacta Group plc, a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer platform, has entered a collaboration and option agreement with ADC Therapeutics SA (Lausanne, CH), a clinical-stage oncology-focused biotechnology company pioneering the development of highly…